Shanghai Lishan Biopharmaceutical

Shanghai Lishan Biopharmaceutical (Lishan Biotech) is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the development of microbiome-based innovative therapies and small molecule drugs. The company leverages its proprietary Swarming technology and the AI-driven Intelligent Microbial Application Platform (IMicAP) to address unmet medical needs in inflammation, oncology, and neurological disorders. Its lead programs include LS-LBP-001 for Crohn's disease and LS-LBP-002 (licensed from Biomica) for renal cell carcinoma, both of which are in Phase 2 clinical development. Lishan Biotech also utilizes an Indolepropionic Acid Small Molecule Platform to discover low-toxicity targets, such as the Pregnane X receptor (PXR) for ulcerative colitis. The company maintains strategic collaborations with academic institutions like Fudan University to advance its AI-integrated drug discovery engine.